Rivaroxaban (Xarelto, BAY59-7939)
11899
Phase 3 small_molecule completed
Quick answer
Rivaroxaban (Xarelto, BAY59-7939) for Venous Thromboembolism is a Phase 3 program (small_molecule) at Bayer HealthCare AG with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer HealthCare AG
- Indication
- Venous Thromboembolism
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed